Therapeutic potential of Vanillylacetone against CCl induced hepatotoxicity by suppressing the serum marker, oxidative stress, inflammatory cytokines and apoptosis in Swiss albino mice
Authors: Tarique Anwer
Mohammad Firoz Alam
Sivakumar Sivagurunathan Moni
Mohammed M Safhi
Gyas Khan
Rahimullah Siddiqui
Journal: Experimental and molecular pathology (2018)
Discipline: CLINICAL MEDICINE
Keywords: Antioxidant enzyme; Apoptosis; Carbon tetrachloride; Free radicals; Hepatotoxicity
Affiliations: Neuroscience and Toxicology Unit, Pharmacology & Toxicology Department, Pharmacy College, Jazan University, Gizan, Saudi Arabia. Electronic address: ., Neuroscience and Toxicology Unit, Pharmacology & Toxicology Department, Pharmacy College, Jazan University, Gizan, Saudi Arabia., Division of Pharmaceutical Biotechnology, Pharmaceutics Department, Pharmacy College, Jazan University, Gizan, Saudi Arabia.

Abstract:  The aim of this research was to investigate the therapeutic potential of Vanillylacetone against carbon tetrachloride (CCl4) induced hepatotoxicity in mice through understanding the serum marker, oxidative stress mechanism and cytokine networks. Carbon tetrachloride is highly hepatotoxic used as research based on animal model. The mice were classified into five groups and each had eight mice. Group-I was controlled and the vehicle was given orally. Group-II was toxic and carbon tetrachloride (1.5 ml/kg) twice a week for 15 days was administered by intra-peritoneal injections. Group- III and IV were pre-treated with Vanillylacetone 50 &amp; 100 mg kg-1 body weight given every day p.o. while, Group-V received only Vanillylacetone (100 mg kg-1 body weight) for 15 days orally. The finding indicates that the administration of CCl4 causes significant elevation of enzyme markers, oxidative stress, inflammatory cytokine and apoptotic markers in Group-II as compared to Group-I. The administration of Vanillylacetone (50 and100 mg kg-1) significantly suppresses the elevated serum enzymes, oxidative stress (TBARS), an inflammatory cytokine (IL2 and TNFα) and apoptotic markers (Caspase-3 and 9) in Group-III and IV as compared to Group-II. It was also noticed that the higher dose of Vanillylacetone (100 mg) is more effective than lower dose of Vanillylacetone (50 mg). There were no significant changes observed with higher dose of Vanillylacetone (100 mg kg-1) in Group-V as compared to Group-I. Histopathological analysis also supported the above findings. Overall, this results shows that Vanillylacetone has a good antioxidant and therapeutic properties which can help in preventing the chemically (CCl4) induced hepatotoxicity. 

Retracted: No

PubPeer comments:
 *[right]* Fig 1A.  Figure 1. Characterization of graphene oxide (GO). (A) Appearance of commercial GO dispersion . *[left]* Fig 1A from [Zhao, Yin Zhang (2020)] .  Figure 1. Characterization of angiopep-2 polypeptide-modified and doxorubicin-loaded graphene oxide (ANG-Dox-GO). (A) The appearance of commercial GO . These appear to be the same bottle, with identical highlights, photographed in front of the same background, at slightly different angles. ![file] The descriptions are surprisingly similar, even accepting that there are only so many ways to describe the appearance of graphene suspension. Respectively,  The color of commercial GO dispersion varied from yellow to brown (Figure 1A). The optical absorption spectra of GO showed absorption peaks at approximately (Figure 1B). As determined by atomic force microscopy, GO was 3-4 nm in thickness and 100- 200 nm in diameter (Figure 1C), suggesting the formation of single or a few layers of GO nanosheets (Figure 1).  The color of commercial GO varies from yellow to brown (Figure 1A). Under a AFM, ANG-Dox-GO was 4-5 nm in thickness and 100-400 nm in diameter (Figure 1B), suggesting the formation of single or several layers of GO nanosheets. In addition, the optical absorption spectra of ANG-Dox-GO showed absorption peaks at approximately 230 nm (Figure 1C). ,